This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

New Data From Phase 3 Studies Provide Additional Evidence Supporting Treatment Effect For Oral BG-12 (Dimethyl Fumarate) In Multiple Sclerosis

Pooled DEFINE and CONFIRM safety data are included in one poster presentation:

  • Safety and Tolerability of BG-12 in Patients with Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Placebo-Controlled Studies was available for viewing on Thursday, Oct. 11 from 3:30-5:00 p.m. CEST

Interim Extension Study Safety Results

Positive interim safety data from ENDORSE, a dose-blind, multi-center, Phase 3 extension study evaluating the long-term safety and efficacy of dimethyl fumarate 240 mg BID and TID, will also be presented at the congress. At the time of analysis, 1,736 patients with RRMS who completed the DEFINE study or the CONFIRM study had been dosed in ENDORSE.

Patients who received two years of dimethyl fumarate in DEFINE and CONFIRM continued on the same dimethyl fumarate dose (BID or TID) in ENDORSE. Patients who had previously received placebo or GA (CONFIRM only) were randomized 1:1 to dimethyl fumarate 240 mg BID or TID.

At the time of analysis, more than half of the patients in ENDORSE had been followed for more than one year. Overall, the safety profile for those first exposed to dimethyl fumarate in ENDORSE was consistent with the safety results established in the DEFINE and CONFIRM studies. There were no new safety signals observed in patients who had previously been on dimethyl fumarate.

In ENDORSE, the incidence of serious infections was low (≤2%) in all treatment groups and there were no opportunistic infections. There was no increased risk of infection in patients treated long-term with dimethyl fumarate. The overall incidence of malignancies was low (<1%). The types and frequency of malignancies that were observed in the treatment groups were expected in the population under study, and no specific pattern of malignancies was observed.

These data are included in one poster presentation:

  • Long-Term Safety and Tolerability of Oral BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis: Interim Results from ENDORSE will be available for viewing on Friday, Oct. 12 from 3:30-5:00 p.m. CEST (late-breaking news)

The data presented at ECTRIMS were included in Biogen Idec’s regulatory submissions for dimethyl fumarate around the world.

3 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,047.17 +68.04 0.40%
S&P 500 1,990.78 +4.27 0.21%
NASDAQ 4,524.5080 -1.9740 -0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs